Engineered immune cells take on lupus in first human test
NCT ID NCT06946485
First seen Nov 01, 2025 · Last updated Apr 30, 2026 · Updated 24 times
Summary
This early-phase study tests a new treatment called CHT101 for people with lupus that has not responded to standard therapies. CHT101 uses specially engineered immune cells (CAR-T cells) to target and attack the faulty cells driving the disease. The study will enroll 15 participants to check if the treatment is safe and whether it can reduce lupus activity.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
RECRUITINGNanjing, Jiangsu, China
Conditions
Explore the condition pages connected to this study.